title: Eligibility of patients with atrial fibrillation for new oral anticoagulants.
authors.forename: Ghassan
authors.initials: G
authors.lastname: Moubarak
authors.forename: Nicolas
authors.initials: N
authors.lastname: Badenco
authors.forename: Julien
authors.initials: J
authors.lastname: Dreyfus
authors.forename: Constantin
authors.initials: C
authors.lastname: Simion
authors.forename: Aurélie
authors.initials: A
authors.lastname: Delos Paquet
authors.forename: Serge
authors.initials: S
authors.lastname: Cazeau
authors.forename: Romain
authors.initials: R
authors.lastname: Cador
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage*; D000069604:Dabigatran; D065427:Factor Xa Inhibitors; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D015091:beta-Alanine; D000069604:Dabigatran